Literature DB >> 31485921

Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection.

Matthias Schneider1, Anna-Laura Potthoff2, Vera C Keil3, Ági Güresir2, Johannes Weller4, Valeri Borger2, Motaz Hamed2, Andreas Waha5, Hartmut Vatter2, Erdem Güresir2, Ulrich Herrlinger4, Patrick Schuss2.   

Abstract

OBJECTIVE: Supra-total glioblastoma resection has gained growing attention with regard to superior long-term disease control. However, aggressive onco-surgical approaches-geared beyond conventional gross total resections (GTR)-are limited by the impairment of adjacent eloquent areas at risk that may entail severe postoperative functional morbidity. Against this backdrop we analyzed our institutional database with regard to potential survival benefits of anterior temporal lobectomy as a paradigm for supra-total resection in patients with precisely temporal-located, non-eloquent glioblastoma.
METHODS: Between 2012 and 2017, 38 patients with isolated temporal glioblastoma underwent GTR or temporal lobectomy at the authors' institution. Both groups of differing resection modalities were compared with regard to postoperative Karnofsky performance score (KPS), progression-free survival (PFS), and overall survival (OS).
RESULTS: Patients with temporal lobectomy exhibited significantly superior median KPS at the 12 months follow-up compared to the GTR group (median KPS of 80 vs. 60, p = 0.04). Temporal lobectomy was associated with significantly prolonged PFS (p = 0.005) and OS (p = 0.002) coming up to 15 months (95% CI 9.7-22.1) and 23 months (95% CI 14.8-34.5) compared to 7 months (95% CI 3.3-8.3) and 11 months (95% CI 9.2-17.9) for the GTR group. Multivariate analysis revealed temporal lobectomy as the only predictor for both superior PFS (p = 0.037, OR 7.3, 95% CI 1.1-47.4) and OS (p = 0.04, OR 7.8, 95% CI 1.1-55.2).
CONCLUSIONS: These results strongly suggest temporal lobectomy as an aggressive supra-total resection policy to constitute the surgical modality of choice for isolated temporal-located glioblastoma.

Entities:  

Keywords:  Glioblastoma; Gross-total resection; Lobectomy; Overall survival

Mesh:

Year:  2019        PMID: 31485921     DOI: 10.1007/s11060-019-03281-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  29 in total

1.  Excision Margins of Melanoma Make a Difference: New Data Support an Old Paradigm.

Authors:  Merrick I Ross; Charles M Balch
Journal:  Ann Surg Oncol       Date:  2015-11-11       Impact factor: 5.344

2.  Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma.

Authors:  Kyle R Noll; Jeffrey S Weinberg; Mateo Ziu; Ronald J Benveniste; Dima Suki; Jeffrey S Wefel
Journal:  Neurosurgery       Date:  2015-11       Impact factor: 4.654

Review 3.  Current concepts and management of glioblastoma.

Authors:  Matthias Preusser; Sandrine de Ribaupierre; Adelheid Wöhrer; Sara C Erridge; Monika Hegi; Michael Weller; Roger Stupp
Journal:  Ann Neurol       Date:  2011-07       Impact factor: 10.422

4.  Semantic access dysphasia resulting from left temporal lobe tumours.

Authors:  Fabio Campanella; Massimo Mondani; Miran Skrap; Tim Shallice
Journal:  Brain       Date:  2008-12-02       Impact factor: 13.501

5.  Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study.

Authors:  Tae Hoon Roh; Seok-Gu Kang; Ju Hyung Moon; Kyoung Su Sung; Hun Ho Park; Se Hoon Kim; Eui Hyun Kim; Chang-Ki Hong; Chang-Ok Suh; Jong Hee Chang
Journal:  J Neurosurg       Date:  2019-03-01       Impact factor: 5.115

6.  Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.

Authors:  Thomas Mikeska; Christoph Bock; Osman El-Maarri; Anika Hübner; Denise Ehrentraut; Johannes Schramm; Jörg Felsberg; Philip Kahl; Reinhard Büttner; Torsten Pietsch; Andreas Waha
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

7.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

Review 8.  Surgical oncology for gliomas: the state of the art.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Nat Rev Clin Oncol       Date:  2017-11-21       Impact factor: 66.675

Review 9.  Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment.

Authors:  Emma van Kessel; Anniek E Baumfalk; Martine J E van Zandvoort; Pierre A Robe; Tom J Snijders
Journal:  J Neurooncol       Date:  2017-05-31       Impact factor: 4.130

Review 10.  Glioblastoma: new therapeutic strategies to address cellular and genomic complexity.

Authors:  Xue Cai; Michael E Sughrue
Journal:  Oncotarget       Date:  2017-12-20
View more
  8 in total

1.  A consensus definition of supratotal resection for anatomically distinct primary glioblastoma: an AANS/CNS Section on Tumors survey of neurosurgical oncologists.

Authors:  Maureen Rakovec; Adham M Khalafallah; Oren Wei; David Day; Jason P Sheehan; Jonathan H Sherman; Debraj Mukherjee
Journal:  J Neurooncol       Date:  2022-08-01       Impact factor: 4.506

Review 2.  Supramarginal Resection for Glioblastoma: It Is Time to Set Boundaries! A Critical Review on a Hot Topic.

Authors:  Francesco Guerrini; Elena Roca; Giannantonio Spena
Journal:  Brain Sci       Date:  2022-05-16

Review 3.  Disconnecting multicellular networks in brain tumours.

Authors:  Varun Venkataramani; Matthias Schneider; Ulrich Herrlinger; Frank Winkler; Frank Anton Giordano; Thomas Kuner; Wolfgang Wick
Journal:  Nat Rev Cancer       Date:  2022-04-29       Impact factor: 69.800

4.  Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection.

Authors:  Matthias Schneider; Patrick Schuss; Valeri Borger; Motaz Hamed; Inja Ilic; Anna-Laura Potthoff; Attila Racz; Niklas Schäfer; Erdem Güresir; Rainer Surges; Ulrich Herrlinger; Hartmut Vatter
Journal:  J Neurooncol       Date:  2021-02-07       Impact factor: 4.130

5.  Postoperative Prolonged Mechanical Ventilation in Patients With Newly Diagnosed Glioblastoma-An Unrecognized Prognostic Factor.

Authors:  Patrick Schuss; Felix Lehmann; Niklas Schäfer; Christian Bode; Elisa Scharnböck; Christina Schaub; Muriel Heimann; Anna-Laura Potthoff; Johannes Weller; Erdem Güresir; Christian Putensen; Hartmut Vatter; Ulrich Herrlinger; Matthias Schneider
Journal:  Front Oncol       Date:  2020-12-18       Impact factor: 6.244

6.  Perioperative red blood cell transfusion is associated with poor functional outcome and overall survival in patients with newly diagnosed glioblastoma.

Authors:  Matthias Schneider; Niklas Schäfer; Anna-Laura Potthoff; Leonie Weinhold; Lars Eichhorn; Johannes Weller; Elisa Scharnböck; Christina Schaub; Muriel Heimann; Erdem Güresir; Felix Lehmann; Hartmut Vatter; Ulrich Herrlinger; Patrick Schuss
Journal:  Neurosurg Rev       Date:  2021-09-04       Impact factor: 3.042

7.  Temporal lobe epilepsy surgery: Piriform cortex resection impacts seizure control in the long-term.

Authors:  Valeri Borger; Motaz Hamed; Majd Bahna; Áttila Rácz; Inja Ilic; Anna-Laura Potthoff; Tobias Baumgartner; Theodor Rüber; Albert Becker; Alexander Radbruch; Florian Mormann; Rainer Surges; Hartmut Vatter; Matthias Schneider
Journal:  Ann Clin Transl Neurol       Date:  2022-07-01       Impact factor: 5.430

8.  A Crowdsourced Consensus on Supratotal Resection Versus Gross Total Resection for Anatomically Distinct Primary Glioblastoma.

Authors:  Adham M Khalafallah; Maureen Rakovec; Chetan Bettegowda; Christopher M Jackson; Gary L Gallia; Jon D Weingart; Michael Lim; Yoshua Esquenazi; Brad E Zacharia; Ezequiel Goldschmidt; Mateo Ziu; Michael E Ivan; Andrew S Venteicher; Edjah K Nduom; Adam N Mamelak; Ray M Chu; John S Yu; Jason P Sheehan; Brian V Nahed; Bob S Carter; Mitchel S Berger; Raymond Sawaya; Debraj Mukherjee
Journal:  Neurosurgery       Date:  2021-09-15       Impact factor: 5.315

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.